{"id":"xanomeline-and-trospium-chloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"8f0e73bf-6025-44f6-ab64-0983322de0df","title":"COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) CAPSULE, COATED PELLETS COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) KIT [E.R. SQUIBB & SONS, L.L.C.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xanomeline selectively activates M1 and M4 muscarinic acetylcholine receptors in the brain to improve cognition and reduce psychotic symptoms. Trospium chloride, a peripheral anticholinergic antagonist, blocks unwanted muscarinic effects in the periphery (such as gastrointestinal and urinary effects) without crossing the blood-brain barrier, thereby improving tolerability while preserving central benefits.","oneSentence":"Xanomeline is a muscarinic M1/M4 receptor agonist combined with trospium chloride, an anticholinergic agent, to enhance cognitive function while mitigating peripheral cholinergic side effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:48.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psychosis in Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT06126224","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-08-28","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":500},{"nctId":"NCT07011732","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-10","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT05980949","phase":"PHASE3","title":"Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-07-11","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":800},{"nctId":"NCT05511363","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-08-23","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":410},{"nctId":"NCT06951711","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-13","conditions":"Bipolar Disorder Type I With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT06929273","phase":"PHASE3","title":"A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-18","conditions":"Bipolar Disorder Type I With Mania","enrollment":450},{"nctId":"NCT06951698","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-11","conditions":"Bipolar-I Disorder With Mania or Mania With Mixed Features","enrollment":274},{"nctId":"NCT06937229","phase":"PHASE3","title":"A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-02","conditions":"Alzheimer Disease, Agitation","enrollment":600},{"nctId":"NCT07101094","phase":"","title":"Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-22","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT05304767","phase":"PHASE3","title":"An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-03-07","conditions":"Schizophrenia","enrollment":280},{"nctId":"NCT07221877","phase":"PHASE4","title":"A Study to Evaluate the Effect of KarXT on Urological Safety","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-20","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT07379827","phase":"","title":"Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-26","conditions":"Schizophrenia","enrollment":1500},{"nctId":"NCT07011745","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-16","conditions":"Alzheimer Disease","enrollment":352},{"nctId":"NCT07084831","phase":"PHASE3","title":"A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia","status":"RECRUITING","sponsor":"European Group for Research In Schizophrenia","startDate":"2026-01-14","conditions":"Schizophrenia; Psychosis, Cognitive Impairment","enrollment":171},{"nctId":"NCT07118215","phase":"PHASE1","title":"A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2025-09-29","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT06729970","phase":"PHASE1","title":"A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-12-26","conditions":"Healthy Volunteers","enrollment":133},{"nctId":"NCT07140913","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-08","conditions":"Mania, Bipolar Disorder","enrollment":424},{"nctId":"NCT07423546","phase":"PHASE1, PHASE2","title":"A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-04-01","conditions":"SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder","enrollment":12},{"nctId":"NCT07257120","phase":"PHASE4","title":"KarXT Concentrations in the Breast Milk and Plasma of Lactating Females","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2026-01-09","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT07284745","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07285798","phase":"PHASE3","title":"A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":176},{"nctId":"NCT07063342","phase":"PHASE1","title":"A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-06-27","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT05919823","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-05-29","conditions":"Schizophrenia","enrollment":202},{"nctId":"NCT07212062","phase":"PHASE2","title":"The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.","status":"NOT_YET_RECRUITING","sponsor":"Neurology Office of South Florida","startDate":"2025-12-01","conditions":"Alzheimers Disease","enrollment":60},{"nctId":"NCT04820309","phase":"PHASE3","title":"An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-06-02","conditions":"Schizophrenia","enrollment":566},{"nctId":"NCT06853171","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-04-29","conditions":"Psychiatric Disorders","enrollment":24},{"nctId":"NCT06605950","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2024-10-01","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT06947941","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-07-31","conditions":"Alzheimer Disease, Psychosis","enrollment":1046},{"nctId":"NCT06923891","phase":"PHASE4","title":"An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients","status":"NOT_YET_RECRUITING","sponsor":"Vanguard Research Group","startDate":"2025-04-16","conditions":"Schizophrenia","enrollment":172},{"nctId":"NCT06924255","phase":"PHASE4","title":"An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Collaborative Neuroscience Research, LLC","startDate":"2025-04","conditions":"Schizophrenia Disorders","enrollment":100},{"nctId":"NCT05145413","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-11-12","conditions":"Schizophrenia","enrollment":396},{"nctId":"NCT04738123","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-04-06","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":256},{"nctId":"NCT04659174","phase":"PHASE3","title":"An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2021-02-01","conditions":"Schizophrenia","enrollment":152},{"nctId":"NCT05643170","phase":"PHASE3","title":"An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia","status":"TERMINATED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-11-08","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT04659161","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2020-12-16","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":252},{"nctId":"NCT03697252","phase":"PHASE2","title":"A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2018-09-18","conditions":"Schizophrenia","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xanomeline and Trospium Chloride","genericName":"Xanomeline and Trospium Chloride","companyName":"Collaborative Neuroscience Research, LLC","companyId":"collaborative-neuroscience-research-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xanomeline is a muscarinic M1/M4 receptor agonist combined with trospium chloride, an anticholinergic agent, to enhance cognitive function while mitigating peripheral cholinergic side effects. Used for Psychosis in Alzheimer's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}